ADH-6 |
| Katalog-Nr.GC64235 |
ADH-6 ist eine Tripyridylamid-Verbindung. ADH-6 hebt die Selbstorganisation der aggregationskernbildenden SubdomÄne von mutiertem p53 DBD auf. ADH-6 zielt auf mutierte p53-Aggregate in menschlichen Krebszellen ab und dissoziiert sie, wodurch die transkriptionelle AktivitÄt von p53 wiederhergestellt wird, was zu Zellzyklusarrest und Apoptose fÜhrt. ADH-6 hat das Potenzial fÜr die Erforschung von Krebserkrankungen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2227429-65-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ADH-6 is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53’s transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 has the potential for the research of cancer diseases[1].
[1]. Palanikumar L, et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat Commun. 2021;12(1):3962.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *